SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
出版年份 2021 全文链接
标题
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
作者
关键词
Imetelstat, Luspatercept, Momelotinib, Myelofibrosis, Navitoclax, Navtemadlin, Pacrtitinib, Pelabresib
出版物
Clinical Lymphoma Myeloma & Leukemia
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-10-14
DOI
10.1016/j.clml.2021.10.002
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Improved survival of patients with myelofibrosis in the last decade: Single‐center experience
- (2022) Lucia Masarova et al. CANCER
- Disease Modification in Myelofibrosis: An Elusive Goal?
- (2022) Pankit Vachhani et al. JOURNAL OF CLINICAL ONCOLOGY
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia
- (2022) Helen T. Chifotides et al. Journal of Hematology & Oncology
- Clinical Significance of Bone Marrow Blast Percentage in Patients with Myelofibrosis and the Effect of Ruxolitinib Therapy
- (2021) Lucia Masarova et al. Clinical Lymphoma Myeloma & Leukemia
- MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
- (2021) Srdan Verstovsek et al. Future Oncology
- Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
- (2021) Jacob Handlos Grauslund et al. Frontiers in Oncology
- Accelerated Phase of Myeloproliferative Neoplasms
- (2021) Omar A. Shahin et al. ACTA HAEMATOLOGICA
- Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
- (2021) Francesca Palandri et al. CANCER
- Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms
- (2021) Naveen Pemmaraju et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Epigenetic Dysregulation of Myeloproliferative Neoplasms
- (2021) Andrew Dunbar et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy
- (2021) Mrinal M. Patnaik et al. LEUKEMIA & LYMPHOMA
- SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis
- (2021) Prithviraj Bose et al. Clinical Lymphoma Myeloma & Leukemia
- MPN-038: PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
- (2021) John Mascarenhas et al. Clinical Lymphoma Myeloma & Leukemia
- MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
- (2021) Ruben Mesa et al. Clinical Lymphoma Myeloma & Leukemia
- Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
- (2021) Srdan Verstovsek et al. HAEMATOLOGICA
- Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
- (2021) John Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).
- (2021) Srdan Verstovsek et al. JOURNAL OF CLINICAL ONCOLOGY
- Paradigm shift: combination BET and JAK inhibition in myelofibrosis
- (2021) John Mascarenhas et al. LEUKEMIA
- Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
- (2021) Léa Sureau et al. Blood Cancer Journal
- TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis
- (2021) Lilian Varricchio et al. JCI Insight
- Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
- (2021) Naveen Pemmaraju et al. Blood Advances
- Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data
- (2021) Andrew T. Kuykendall et al. ANNALS OF HEMATOLOGY
- Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
- (2021) Srdan Verstovsek et al. ANNALS OF HEMATOLOGY
- Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data
- (2021) Srdan Verstovsek et al. BLOOD
- Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis
- (2021) Prithviraj Bose et al. BLOOD
- Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
- (2021) Marina Kremyanskaya et al. BLOOD
- Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
- (2021) John Mascarenhas et al. BLOOD
- PD-1 inhibition in advanced myeloproliferative neoplasms
- (2021) Gabriela Hobbs et al. Blood Advances
- The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
- (2020) Bridget K. Marcellino et al. Clinical Lymphoma Myeloma & Leukemia
- Management of myelofibrosis after ruxolitinib failure
- (2020) Claire N Harrison et al. ANNALS OF HEMATOLOGY
- Secondary leukemia to myeloproliferative neoplasms
- (2020) Andrew Dunbar et al. BLOOD
- Management of challenging myelofibrosis after JAK inhibitor failure and/or progression
- (2020) Robyn M. Scherber et al. BLOOD REVIEWS
- Clinical outcomes of IDH2 ‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib
- (2020) Anand A. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.
- (2020) Nehal J. Lakhani et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
- (2020) Yoshinori Ozono et al. LEUKEMIA
- Management of myelofibrosis after ruxolitinib failure
- (2020) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis
- (2020) John Mascarenhas et al. JOURNAL OF MEDICAL ECONOMICS
- Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era
- (2020) Lucia Masarova et al. CANCER
- Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
- (2020) Jessica Petiti et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
- (2020) Moshe Talpaz et al. LEUKEMIA
- PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN
- (2020) Friederike Pastore et al. Cancer Discovery
- Fedratinib in myelofibrosis
- (2020) Ann Mullally et al. Blood Advances
- Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
- (2020) Prithviraj Bose et al. Cancers
- Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
- (2020) Steven De Almeida et al. Cancers
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- (2020) Stephen T. Oh et al. Blood Advances
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
- (2020) Aaron T. Gerds et al. Blood Advances
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
- (2019) Naveen Pemmaraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab
- (2019) Takaaki Maekawa et al. BLOOD
- Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms
- (2019) Cansu Cimen Bozkus et al. Cancer Discovery
- Mutant calreticulin in myeloproliferative neoplasms
- (2019) Joan How et al. BLOOD
- Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
- (2019) Prithviraj Bose Expert Opinion on Orphan Drugs
- Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
- (2019) Naveen Pemmaraju et al. BLOOD
- The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
- (2019) Srdan Verstovsek et al. BLOOD
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
- (2019) Raajit K. Rampal et al. BLOOD
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
- (2018) Lucia Masarova et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- (2018) Chengyuan Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
- (2018) Anna Sophia McKenney et al. JOURNAL OF CLINICAL INVESTIGATION
- Pacritinib to treat myelofibrosis patients with thrombocytopenia
- (2018) Douglas Tremblay et al. Expert Review of Hematology
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Management of Myelofibrosis-Related Cytopenias
- (2018) Prithviraj Bose et al. Current Hematologic Malignancy Reports
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis
- (2018) Lucia Masarova et al. BLOOD
- Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis
- (2018) Dongqing Yan et al. CLINICAL CANCER RESEARCH
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis
- (2017) G Mosoyan et al. LEUKEMIA
- Immunotherapy based approaches in myelofibrosis
- (2017) Lucia Masarova et al. Expert Review of Hematology
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
- (2016) Srdan Verstovsek et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
- (2016) S Verstovsek et al. LEUKEMIA
- BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
- (2016) D T Saenz et al. LEUKEMIA
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
- (2014) Neha Bhagwat et al. BLOOD
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms
- (2013) T. Tadmor et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
- (2013) Niccolò Bartalucci et al. Clinical Lymphoma Myeloma & Leukemia
- Anti-transforming growth factor-β therapy in patients with myelofibrosis
- (2013) John Mascarenhas et al. LEUKEMIA & LYMPHOMA
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation
- (2011) Fan Liu et al. CANCER CELL
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
- (2011) W. Fiskus et al. CLINICAL CANCER RESEARCH
- JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
- (2011) M Nakatake et al. ONCOGENE
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
- (2010) Sachie Marubayashi et al. JOURNAL OF CLINICAL INVESTIGATION
- Low-dose thalidomide in myelofibrosis
- (2008) R. Weinkove et al. HAEMATOLOGICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started